Fair value · Chemours Co (CC) · updated 2026-10-03 · from 10-K FY2025
Chemours trades at $13.71. That price implies 17.6× EV/EBITDA and a 3.7% free-cash-flow yield.
Cboe · delayed 15 min · as of 06:01 ET
Are those assumptions reasonable? Use CC’s filed growth history and the AI chat to decide, then set your own inputs below — the range you build is yours.
What the price implies
- EV/EBITDA
- 17.6×
- FCF yield
- 3.7%
(market cap + net debt) ÷ EBITDA
free cash flow ÷ enterprise value (26.8× EV/FCF)
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings. This price: Cboe · delayed 15 min · as of 06:01 ET.
The filing behind these numbers
Chemours Co- Revenue
- $5.8B
- Diluted EPS
- $-2.57
- Free cash flow
- $51.0M
- operating cash flow − capital expenditure
- Diluted shares
- 150.2M
- weighted average
10-K FY2025 · fiscal year ended 2025-12-31 · filed 2026-02-24 · accession 0001193125-26-065201
Trailing-twelve-month EPS also uses the quarterly 10-Qs through Q2 FY2026 (filed 2026-08-05).
Open this filing on sec.govNeed CC data in your own agent or pipeline?
The valuation data behind this page — DCF fair value, margin of safety, PE vs industry, analyst estimates — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.